Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $5.47 USD
Change Today +0.04 / 0.74%
Volume 20.1K
SVA On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 10:32 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

sinovac biotech ltd (SVA) Snapshot

Open
$5.42
Previous Close
$5.43
Day High
$5.51
Day Low
$5.38
52 Week High
08/17/15 - $6.00
52 Week Low
09/30/14 - $4.51
Market Cap
301.4M
Average Volume 10 Days
142.0K
EPS TTM
$0.02
Shares Outstanding
55.1M
EX-Date
--
P/E TM
270.2x
Dividend
--
Dividend Yield
--
Current Stock Chart for SINOVAC BIOTECH LTD (SVA)

sinovac biotech ltd (SVA) Related Businessweek News

No Related Businessweek News Found

sinovac biotech ltd (SVA) Details

Sinovac Biotech Ltd., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of vaccines against hepatitis A, hepatitis B, influenza viruses, and mumps in the People's Republic of China. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine; Split viron pandemic influenza vaccine; and RabEnd, an animal rabies vaccine. The company also develops the EV71 vaccine, which has completed Phase III clinical trial. In addition, it has completed pre-clinical studies for varicella, sabin inactivated polio, and hepatitis A and B vaccines; and focuses on commencing clinical trials for pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, and rubella vaccine. The company has a collaboration agreement with Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and a license agreement with Medimmune, LLC to use patented reverse genetics technology pertaining to H5N1 influenza virus strain production for vaccines. Sinovac Biotech Ltd. was founded in 1999 and is headquartered in Beijing, the People's Republic of China.

668 Employees
Last Reported Date: 04/29/15
Founded in 1999

sinovac biotech ltd (SVA) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

sinovac biotech ltd (SVA) Key Developments

Sinovac Biotech Ltd. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Sinovac Biotech Ltd. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company's sales were $18.5 million, an increase of 53.1% from $12.1 million in the prior year period. The sales increase is mainly attributable to increased sales of Healive and Bilive into the private pay market, and supported by increased sales into the public market as well. Net income attributable to common shareholders was $2.3 million, or $0.04 per basic and diluted share, compared to net loss attributable to common shareholders of $2.2 million, or $0.04 per basic and diluted share, in the second quarter of 2014. Operating income was $3.99 million compared with operating loss of $2.95 million a year ago. Income before income taxes and non-controlling interests was $3.9 million compared with loss of $2.95 million a year ago. Net cash provided by operating activities was $0.42 million compared with net cash used in operating activities of $5.6 million a year ago. Acquisition of property, plant and equipment was $1.1 million compared with $3.5 million a year ago. For the first half, the company's total sales were $27.8 million, an increase of 8.4% from $25.6 million in the same period of 2014. The increase is primarily due to increased sales of Bilive into the private pay market. Net income attributable to common shareholders in the first half of 2015 was $20,000, or $0.00 per basic and diluted share, compared to a net loss of $2.2 million, or $0.04 per basic and diluted share, in the same period of 2014. Net cash used in operating activities was $7.8 million in the first half of 2015. Operating income was $1.79 million compared with operating loss of $2.34 million a year ago. Income before income taxes and non-controlling interests was $1.6 million compared with loss of $2.2 million a year ago. Net cash used in operating activities was $7.8 million compared with net cash used in operating activities of $11.4 million a year ago. Acquisition of property, plant and equipment was $2.8 million compared with $5.7 million a year ago.

Sinovac Biotech Ltd. to Report Q2, 2015 Results on Aug 12, 2015

Sinovac Biotech Ltd. announced that they will report Q2, 2015 results at 5:00 PM, China Standard Time on Aug 12, 2015

Sinovac Biotech Ltd., Q2 2015 Earnings Call, Aug 13, 2015

Sinovac Biotech Ltd., Q2 2015 Earnings Call, Aug 13, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SVA:US $5.47 USD +0.04

SVA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Hualan Biological Engineering Inc CNY39.65 CNY +2.32
ImmunoCellular Therapeutics Ltd $0.43 USD +0.03
Northwest Biotherapeutics Inc $8.32 USD +0.02
Opexa Therapeutics Inc $0.37 USD -0.008
StemCells Inc $0.40 USD +0.012
View Industry Companies
 

Industry Analysis

SVA

Industry Average

Valuation SVA Industry Range
Price/Earnings 100.0x
Price/Sales 4.6x
Price/Book 2.3x
Price/Cash Flow 210.1x
TEV/Sales 2.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SINOVAC BIOTECH LTD, please visit www.sinovac.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.